Evofem Biosciences, Inc. Common Stock
EVFM
EVFM was delisted on the 10th of August, 2022.
17 hedge funds and large institutions have $1.68M invested in Evofem Biosciences, Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 6 closing their positions.
614% more capital invested
Capital invested by funds: $235K → $1.68M (+$1.44M)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
15% less funds holding
Funds holding: 20 → 17 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAD
Craig A. Drill
|
+$1.33M |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$41.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$11.3K |
| 4 |
Bank of New York Mellon
New York
|
+$10.2K |
| 5 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
+$1.25K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARTA
A.R.T. Advisors
New York
|
-$38.4K |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$29.7K |
| 3 |
Nomura Holdings
Tokyo,
Japan
|
-$8K |
| 4 |
Two Sigma Advisers
New York
|
-$8K |
| 5 |
Goldman Sachs
New York
|
-$6K |
EVFM Hedge Fund Activity: Q2 2016 in Review
17 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q2 2016, worth a combined $1.68M — up 614% from $235K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of EVFM and 3 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 4 added.
The largest buyer was Craig A. Drill, opening a new position worth an estimated $1.33M. The largest seller was A.R.T. Advisors, cutting an estimated $38.4K.
- 17 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q2 2016, down from 20 in Q1 2016.
- Funds reported $1.68M of Evofem Biosciences, Inc. Common Stock stock for Q2 2016, up 614% quarter-over-quarter.
- 3 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q2 2016 and 6 closed out, a net change of -3 holders.
- The largest Evofem Biosciences, Inc. Common Stock buyer in Q2 2016 was Craig A. Drill, an estimated $1.33M added.
- The largest Evofem Biosciences, Inc. Common Stock seller in Q2 2016 was A.R.T. Advisors, an estimated $38.4K sold.
Based on aggregated 13F filings for Q2 2016.